• Consensus Rating: Buy
  • Consensus Price Target: $3.62
  • Forecasted Upside: 490.96%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.61
▼ -0.03 (-4.67%)

This chart shows the closing price for EVGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evogene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVGN

Analyst Price Target is $3.62
▲ +490.96% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Evogene in the last 3 months. The average price target is $3.62, with a high forecast of $6.00 and a low forecast of $1.85. The average price target represents a 490.96% upside from the last price of $0.61.

This chart shows the closing price for EVGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Evogene. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/2/2023Alliance Global PartnersInitiated CoverageBuy$1.85Low
8/18/2023Lake Street CapitalBoost TargetBuy ➝ Buy$2.00 ➝ $3.00Low
7/21/2023Roth MkmBoost TargetBuy$1.00 ➝ $6.00Low
5/2/2023Lake Street CapitalInitiated CoverageBuyLow
9/12/2022AegisLower TargetBuy$10.00 ➝ $8.00Low
9/2/2022Roth CapitalLower Target$6.00 ➝ $3.00Low
11/24/2021Royal Bank of CanadaLower TargetOutperform$8.00 ➝ $7.00Low
10/8/2021Roth CapitalInitiated CoverageBuy$7.00High
8/23/2021Royal Bank of CanadaInitiated CoverageOutperform$8.00Low
7/29/2021AegisInitiated CoverageBuy$10.00Medium
11/30/2020Cantor FitzgeraldInitiated CoverageOverweight$9.00High
(Data available from 4/21/2019 forward)

News Sentiment Rating

-0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2024
  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/21/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Evogene logo
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Read More

Today's Range

Now: $0.61
Low: $0.61
High: $0.66

50 Day Range

MA: $0.80
Low: $0.61
High: $0.98

52 Week Range

Now: $0.61
Low: $0.45
High: $1.44

Volume

72,152 shs

Average Volume

77,199 shs

Market Capitalization

$25.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Evogene?

The following equities research analysts have issued reports on Evogene in the last twelve months: Alliance Global Partners, Lake Street Capital, Roth Mkm, and StockNews.com.
View the latest analyst ratings for EVGN.

What is the current price target for Evogene?

3 Wall Street analysts have set twelve-month price targets for Evogene in the last year. Their average twelve-month price target is $3.62, suggesting a possible upside of 491.0%. Roth Mkm has the highest price target set, predicting EVGN will reach $6.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $1.85 for Evogene in the next year.
View the latest price targets for EVGN.

What is the current consensus analyst rating for Evogene?

Evogene currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EVGN will outperform the market and that investors should add to their positions of Evogene.
View the latest ratings for EVGN.

What other companies compete with Evogene?

How do I contact Evogene's investor relations team?

Evogene's physical mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 76121. The biotechnology company's listed phone number is (728) 931-1900 and its investor relations email address is [email protected]. The official website for Evogene is www.evogene.com. Learn More about contacing Evogene investor relations.